EnteroBiotix

EnteroBiotix is a clinical-stage biopharmaceutical company based in Glasgow, Scotland, that develops full-spectrum microbiome-modulating therapeutics to treat severe gastrointestinal diseases, liver cirrhosis, and drug-resistant bacterial infections. The organization utilizes high-diversity microbial products to fortify the human gut microbiome, advancing these targeted treatments through multiple clinical trials, including a recently initiated Phase 2 study for irritable bowel syndrome. Operating with a workforce of approximately 50 employees across its facilities, the enterprise has secured over £47 million in total funding to scale its manufacturing capabilities and clinical pipeline. This capitalization includes a recent £27 million financing package backed by a syndicate of institutional investors, featuring recognizable names such as the Scottish National Investment Bank, Scottish Enterprise, the University of Aberdeen, and Kineticos Life Sciences. EnteroBiotix was founded in 2017 by chief executive officer Dr. James McIlroy.